2026-01-02 - Analysis Report
Okay, here's a breakdown and analysis of UnitedHealth Group (UNH) based on the provided data.

**0. Report in English**

I will present the numerical data first, followed by a simple analysis.

**1. Return Rate Comparison: UNH vs. S&P 500 (VOO)**

*   **Ticker:** UNH
*   **Company Name:** UnitedHealth Group Inc.
*   **Overview:** UnitedHealth Group is a diversified health care company providing health benefits and health services.
*   **UNH Cumulative Return:** -21.89%
*   **VOO (S&P 500) Cumulative Return:** 105.07%
*   **Divergence:**
    *   Max: 22.4
    *   Min: -137.7
    *   Current: -127.0
    *   Relative Divergence: 6.7

**Analysis:**

*   UNH has significantly underperformed the S&P 500. The divergence highlights this substantial difference in returns.
*   The relative divergence of 6.7 indicates that the current level of underperformance is near the worst it has been in the examined period, suggesting potentially oversold conditions *or* a fundamental shift in the company's prospects relative to the broader market.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha    | Beta  | Cap(B) |
| :----------- | :------ | :------ | :------- | :---- | :----- |
| 2016-2018  | 116.0%  | 72.2% | 87.0%  | 0.9   | 225.7  |
| 2017-2019  | 81.0%   | 73.3% | 40.0%  | 0.9   | 266.3  |
| 2018-2020  | 48.0%   | 82.8% | 15.0%  | 1.1   | 317.7  |
| 2019-2021  | 86.0%   | 82.8% | 10.0%  | 1.1   | 454.9  |
| 2020-2022  | 95.0%   | 81.4% | 76.0%  | 0.9   | 480.3  |
| 2021-2023  | 58.0%   | 80.4% | 29.0%  | 0.5   | 476.9  |
| 2022-2024  | 7.0%    | 80.4% | -23.0% | 0.4   | 458.2  |
| 2023-2025  | -34.0%  | 87.8% | -102.0% | 0.3   | 299.0  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Shows significant decline recently, with the 2023-2025 period showing a substantial loss.
*   **MDD (Maximum Drawdown):** High MDD values across all periods suggest significant price volatility and risk.
*   **Alpha:**  The alpha has turned sharply negative in the last two periods, indicating underperformance relative to its benchmark even when adjusted for risk (beta).
*   **Beta:** The beta has decreased, suggesting that UNH's price is becoming less correlated with the overall market.
*   **Cap(B) (Market Capitalization in Billions):**  Shows a large decrease in the most recent period.

**2. Recent Stock Price Fluctuations**

*   **Close:** 330.11
*   **Last Market Data:** {'price': 330.11, 'previousClose': 332.16, 'change': -0.62}
*   **5-day SMA:** 330.124
*   **20-day SMA:** 331.067
*   **60-day SMA:** 337.7943

**Analysis:**

*   The stock price is currently below its 5-day, 20-day, and 60-day simple moving averages.  This suggests a short-term downtrend.
*   The 'change' value shows a minor decrease in the most recent trading session.

**3. RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment Recommended)
*   **RSI:** 51.90 (Neutral - Neither overbought nor oversold)
*   **PPO:** 0.0659 (Positive, but close to zero, indicating limited momentum)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80) Dividend_2.21 (Cash Ratio: 0% on 2025-12-08)
*   **Recent (20 days) relative divergence change:** 1.9 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** 0.0 (no expected excess return vs. S&P 500 for long-term investment)

**Analysis:**

*   The MRI suggests a medium investment recommendation.
*   The RSI is relatively neutral, indicating no strong overbought or oversold condition.
*   The positive PPO indicates a slightly bullish trend.
*   The Hybrid Signal suggests a "Buy" recommendation, but with a high cash allocation due to the level of risks.
*   Despite a short-term increase in relative divergence, the expected return is zero, meaning UNH is not expected to outperform the S&P 500 in the long term.

**4. Recent News & Significant Events (Yahoo Finance)**

*   **Negative News:** A few headlines highlight risks and underperformance:
    *   UnitedHealthcare delays remote monitoring policy.
    *   Forbes: "3 Risks That Can Make UnitedHealth Stock Unattractive".
*   **Mixed/Neutral News:**
    *   Comparison of UNH vs. ELV (Elevance Health) - suggests the sector is under scrutiny.
    *   "UnitedHealth: Valuation Is Reset, Bull Case Is Still Standing Tall" - This offers a counterpoint to the negative news, suggesting some analysts remain positive.
    *   "UNH rises after hours as traders look ahead to January guidance" - Short-term positive reaction.
*   **Billionaire selling:**  David Tepper selling UNH could be a cause for concern.

**Analysis:** The news is mixed, but leans towards caution. Negative headlines and a billionaire selling shares raise red flags, while some analysts maintain a positive outlook.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.96 (~Buy)
*   **Opinions:** 25
*   **Target Price (avg/high/low):** 392.24 / 440.00 / 280.00
*   **Recent Rating Changes:** (No changes provided)

**Analysis:**

*   The analyst consensus is still "Buy," with a mean rating suggesting a generally positive outlook.
*   The average target price of $392.24 suggests potential upside from the current price. However, the wide range between the high and low target prices indicates uncertainty.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
| :--------- | :--- | :--------- |
| 2025-10-28 | 2.59 | 113.16 B$  |
| 2025-08-11 | 3.76 | 111.62 B$  |
| 2025-05-07 | 6.9  | 109.58 B$  |
| 2024-11-04 | 6.56 | 100.82 B$  |
| 2025-10-28 | 6.56 | 100.82 B$  |

**Analysis:**

*   Revenues show consistent increase.
*   However, the EPS shows fluctuation.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
| :----------- | :---------- | :------------ |
| 2025-09-30 | $113.16B  | 18.24%        |
| 2025-06-30 | $111.62B  | 17.93%        |
| 2025-03-31 | $109.58B  | 21.70%        |
| 2024-12-31 | $100.81B  | 21.14%        |
| 2024-09-30 | $100.82B  | 22.84%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
| :----------- | :-------- | :---- |
| 2025-09-30 | $95.79B | 2.45% |
| 2025-06-30 | $94.72B | 3.60% |
| 2025-03-31 | $95.04B | 6.62% |
| 2024-12-31 | $92.66B | 5.98% |
| 2024-09-30 | $94.53B | 6.41% |

**Analysis:**

*   Revenue is growing consistently.
*   Profit margins have decreased in the last few quarters.
*   Equity has increased slightly overall.
*   ROE (Return on Equity) has decreased significantly, indicating lower profitability relative to shareholder equity.

**7. Comprehensive Analysis (Summary)**

UnitedHealth Group (UNH) presents a mixed picture:

*   **Negative Performance:**  UNH has significantly underperformed the S&P 500 recently.  CAGR, Alpha, and Market Capitalization are all down significantly in the most recent periods.
*   **Technical Indicators:**  The stock is in a short-term downtrend, but the RSI is neutral.
*   **News Sentiment:**  Recent news leans negative, with concerns about policy changes, risks, and a notable investor selling shares.
*   **Analyst Opinion:**  Analysts remain generally positive, but target prices vary widely, reflecting uncertainty.
*   **Financials:**  Revenue is growing, but profit margins and ROE are declining, raising concerns about profitability.

**Conclusion:**

While analysts maintain a "Buy" rating, the data suggests caution is warranted. UNH's underperformance, negative news flow, and declining profitability metrics raise significant concerns. The company appears to be facing headwinds that are negatively impacting its stock price and financial performance. Investors should carefully consider these factors before investing. The Hybrid Signal, despite suggesting a "Buy", highlights the risks by suggesting only a partial investment (90% of cash).


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.